All In Biotech

NDA 208411 · Emergent

Narcan

Naloxone Hydrochloride · Nasal

Priority review

Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Nov 18, 2015

Approved uses

3

Original approval plus efficacy supplements

Registered trials

682

129 Phase 3, 31 recruiting

FAERS reports

4,866

3,463 serious, 743 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 17, 2026.

Uses to “revive” someone during an overdose from many prescription pain medications or street drugs such as heroin this medicine can save a life

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • NARCAN · NALOXONE HYDROCHLORIDE 4MG/SPRAY · SPRAY, METERED, NASAL · Over-the-counter · TE AB
  • NARCAN · NALOXONE HYDROCHLORIDE 2MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SPRAY, METERED, NASAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Naloxone" as an intervention, any sponsor and status, largest first.

All 682 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea389
  • fatigue365
  • pain347
  • death301
  • vomiting291
  • diarrhoea272
  • dyspnoea248
  • off label use245
  • toxicity to various agents230
  • drug ineffective223
  • headache219
  • overdose213

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
200512
20069
200718
200833
200924
201037
201139
201237
201321
201443
201555
2016186
2017110
2018245
2019330
2020644
2021508
2022477
2023521
2024538
2025608
2026361

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Narcan (Naloxone HCl)

2024 spending

$1.1M

Beneficiaries

8,436

9,543 claims

Per beneficiary

$125

$55.07 per unit

View as table
YearSpending
2020$53,370,720
2021$63,707,064
2022$12,345,513
2023$2,201,538
2024$1,053,790

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,735 on PubMed

Sponsor: Emergent

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.